{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:49:59Z","timestamp":1790423399884,"version":"4.1.0"},"reference-count":100,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2017,9,11]],"date-time":"2017-09-11T00:00:00Z","timestamp":1505088000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hepatology Communications"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:p>Cholestatic drug\u2010induced liver injury (DILI) can be a diagnostic challenge due to a large differential diagnosis, variability in clinical presentation, and lack of serologic biomarkers associated with this condition. The clinical presentation of drug\u2010induced cholestasis includes bland cholestasis, cholestatic hepatitis, secondary sclerosing cholangitis, and vanishing bile duct syndrome. The associate mortality of cholestatic DILI can be as high as 10%, and thus prompt recognition and removal of the offending agent is of critical importance. Several risk factors have been identified for drug\u2010induced cholestasis, including older age, genetic determinants, and properties of certain medications. Antibiotics, particularly amoxicillin\/clavulanate, remain the predominant cause of cholestatic DILI, although a variety of other medications associated with this condition have been identified. In this review, we summarize the presentation, clinical approach, risk factors, implicated medications, and management of drug\u2010induced cholestatic liver injury. (<jats:italic toggle=\"yes\">Hepatology Communications<\/jats:italic> 2017;1:726\u2013735)<\/jats:p>","DOI":"10.1002\/hep4.1088","type":"journal-article","created":{"date-parts":[[2017,9,11]],"date-time":"2017-09-11T15:25:12Z","timestamp":1505143512000},"page":"726-735","source":"Crossref","is-referenced-by-count":122,"title":["Drug\u2010induced cholestasis"],"prefix":"10.1097","volume":"1","author":[{"given":"Vinay","family":"Sundaram","sequence":"first","affiliation":[{"name":"Department of Medicine and Comprehensive Transplant Center,Cedars\u2010Sinai Medical Center,Los Angeles,CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar S.","family":"Bj\u00f6rnsson","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology and Hepatology, Department of Internal Medicine,National University Hospital of Iceland,Reykjav\u00edk,Iceland"},{"name":"Faculty of Medicine and School of Education,University of Iceland,Reykjav\u00edk,Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,9,11]]},"reference":[{"key":"hep41088-bib-0001-20240114","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.cld.2012.03.012","article-title":"Approach to a patient with elevated serum alkaline phosphatase","volume":"16","year":"2012","journal-title":"Clin Liv Dis"},{"key":"hep41088-bib-0002-20240114","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/MOG.0b013e3283383c7c","article-title":"Drug\u2010induced liver injury: a clinical update","volume":"26","year":"2010","journal-title":"Curr Opin Gastroenterol"},{"key":"hep41088-bib-0003-20240114","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/0895-4356(93)90102-7","article-title":"Causality assessment of adverse reactions to drugs\u2013II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge","volume":"46","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"hep41088-bib-0004-20240114","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0889-8553(21)00228-4","article-title":"Mechanisms of drug\u2010induced liver disease","volume":"24","year":"1995","journal-title":"Gastroenterol Clin North Am"},{"key":"hep41088-bib-0005-20240114","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ajg.2014.131","article-title":"ACG clinical guideline: the diagnosis and management of idiosyncratic drug\u2010induced liver injury","volume":"109","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"hep41088-bib-0006-20240114","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cld.2012.11.002","article-title":"Drug\u2010induced cholestasis","volume":"17","year":"2013","journal-title":"Clin Liver Dis"},{"key":"hep41088-bib-0007-20240114","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/jhep.2002.34857","article-title":"Incidence of drug\u2010induced hepatic injuries: a French population\u2010based study","volume":"36","year":"2002","journal-title":"Hepatology"},{"key":"hep41088-bib-0008-20240114","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1055\/s-0029-1240005","article-title":"The pathology of drug\u2010induced liver injury","volume":"29","year":"2009","journal-title":"Semin Liver Dis"},{"key":"hep41088-bib-0009-20240114","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.26709","article-title":"Hepatic histological findings in suspected drug\u2010induced liver injury: systematic evaluation and clinical associations","volume":"59","year":"2014","journal-title":"Hepatology"},{"key":"hep41088-bib-0010-20240114","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/hep.28967","article-title":"Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements","volume":"65","year":"2017","journal-title":"Hepatology"},{"key":"hep41088-bib-0011-20240114","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/hep.1840200610","article-title":"Chlorpromazine\u2010induced vanishing bile duct syndrome leading to biliary cirrhosis","volume":"20","year":"1994","journal-title":"Hepatology"},{"key":"hep41088-bib-0012-20240114","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/hep.20800","article-title":"Outcome and prognostic markers in severe drug\u2010induced liver disease","volume":"42","year":"2005","journal-title":"Hepatology"},{"key":"hep41088-bib-0013-20240114","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/ajg.2015.283","article-title":"Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury","volume":"110","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"hep41088-bib-0014-20240114","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/hep.22895","article-title":"Phenotypic characterization of idiosyncratic drug\u2010induced liver injury: the influence of age and sex","volume":"49","year":"2009","journal-title":"Hepatology"},{"key":"hep41088-bib-0015-20240114","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/hep.21359","article-title":"Hepatobiliary transporters and drug\u2010induced cholestasis","volume":"44","year":"2006","journal-title":"Hepatology"},{"key":"hep41088-bib-0016-20240114","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jhep.2005.03.017","article-title":"Enterohepatic transport of bile salts and genetics of cholestasis","volume":"43","year":"2005","journal-title":"J Hepatol"},{"key":"hep41088-bib-0017-20240114","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/01.fpc.0000230418.28091.76","article-title":"Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug\u2010induced liver injury","volume":"17","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"hep41088-bib-0018-20240114","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJM199810223391707","article-title":"Molecular pathogenesis of cholestasis","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"hep41088-bib-0019-20240114","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","article-title":"Causality assessment of adverse reactions to drugs\u2013I. A novel method based on the conclusions of international consensus meetings: application to drug\u2010induced liver injuries","volume":"46","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"hep41088-bib-0020-20240114","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1055\/s-0029-1240003","article-title":"Causality assessment in drug\u2010induced liver injury","volume":"29","year":"2009","journal-title":"Semin Liver Dis"},{"key":"hep41088-bib-0021-20240114","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jhep.2010.12.041","article-title":"Recurrent drug\u2010induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis","volume":"55","year":"2011","journal-title":"J Hepatol"},{"key":"hep41088-bib-0022-20240114","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/hep.22442","article-title":"Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug\u2010induced liver injury","volume":"48","year":"2008","journal-title":"Hepatology"},{"key":"hep41088-bib-0023-20240114","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.cld.2013.07.015","article-title":"Drug\u2010induced cholestasis","volume":"17","year":"2013","journal-title":"Clin Liver Dis"},{"key":"hep41088-bib-0024-20240114","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/MEG.0b013e32832b8e10","article-title":"Stevens\u2010Johnson syndrome and cholestatic hepatitis induced by acute Epstein\u2010Barr virus infection","volume":"23","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"hep41088-bib-0025-20240114","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1476-0711-10-35","article-title":"Cholestatic hepatitis in a patient with typhoid fever \u2010 a case report","volume":"10","year":"2011","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"hep41088-bib-0026-20240114","doi-asserted-by":"crossref","first-page":"141","DOI":"10.5009\/gnl.2009.3.2.141","article-title":"A case of acute q Fever with severe acute cholestatic hepatitis","volume":"3","year":"2009","journal-title":"Gut Liver"},{"key":"hep41088-bib-0027-20240114","first-page":"64","article-title":"The burden of acute nonfulminant drug\u2010induced hepatitis in a United States tertiary referral center [corrected]","volume":"39","year":"2005","journal-title":"J Clin Gastroenterol"},{"key":"hep41088-bib-0028-20240114","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.3748\/wjg.v20.i28.9418","article-title":"Atypical causes of cholestasis","volume":"20","year":"2014","journal-title":"World J Gastroenterol"},{"key":"hep41088-bib-0029-20240114","first-page":"gov061","article-title":"Severe cholestatic hepatitis due to large vessel vasculitis: report of two cases","volume":"pii","year":"2015","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"hep41088-bib-0030-20240114","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/hep.22272","article-title":"Relationship between daily dose of oral medications and idiosyncratic drug\u2010induced liver injury: search for signals","volume":"47","year":"2008","journal-title":"Hepatology"},{"key":"hep41088-bib-0031-20240114","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/hep.23317","article-title":"Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events","volume":"51","year":"2010","journal-title":"Hepatology"},{"key":"hep41088-bib-0032-20240114","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.gastro.2005.05.006","article-title":"Drug\u2010induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10\u2010year period","volume":"129","year":"2005","journal-title":"Gastroenterology"},{"key":"hep41088-bib-0033-20240114","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.21214","article-title":"Interindividual variability of canalicular ATP\u2010binding\u2010cassette (ABC)\u2010transporter expression in human liver","volume":"44","year":"2006","journal-title":"Hepatology"},{"key":"hep41088-bib-0034-20240114","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","article-title":"Features and outcomes of 899 patients with drug\u2010induced liver injury: the DILIN Prospective Study","volume":"148","year":"2015","journal-title":"Gastroenterology"},{"key":"hep41088-bib-0035-20240114","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0016-5085(97)70193-8","article-title":"Recurrent familial prolonged intrahepatic cholestasis of pregnancy associated with chronic liver disease","volume":"113","year":"1997","journal-title":"Gastroenterology"},{"key":"hep41088-bib-0036-20240114","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF02598014","article-title":"Hepatobiliary complications of oral contraceptives","volume":"7","year":"1992","journal-title":"J Gen Intern Med"},{"key":"hep41088-bib-0037-20240114","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/0016-5085(92)90335-V","article-title":"Effects of long\u2010term rifampicin administration in primary biliary cirrhosis","volume":"102","year":"1992","journal-title":"Gastroenterology"},{"key":"hep41088-bib-0038-20240114","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/gut.50.3.436","article-title":"Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis","volume":"50","year":"2002","journal-title":"Gut"},{"key":"hep41088-bib-0039-20240114","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0016-5085(99)70404-X","article-title":"HLA association of amoxicillin\u2010clavulanate\u2013induced hepatitis","volume":"117","year":"1999","journal-title":"Gastroenterology"},{"key":"hep41088-bib-0040-20240114","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/hep.20215","article-title":"HLA class II genotype influences the type of liver injury in drug\u2010induced idiosyncratic liver disease","volume":"39","year":"2004","journal-title":"Hepatology"},{"key":"hep41088-bib-0041-20240114","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ng.379","article-title":"HLA\u2010B*5701 genotype is a major determinant of drug\u2010induced liver injury due to flucloxacillin","volume":"41","year":"2009","journal-title":"Nat Genet"},{"key":"hep41088-bib-0042-20240114","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3748\/wjg.14.38","article-title":"Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive\u2010induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump","volume":"14","year":"2008","journal-title":"World J Gastroenterol"},{"key":"hep41088-bib-0043-20240114","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/hep.1840150212","article-title":"Drug\u2010induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia","volume":"15","year":"1992","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"hep41088-bib-0044-20240114","first-page":"31","article-title":"Vanishing bile duct syndrome in drug\u2010induced liver disease","volume":"26","year":"1997","journal-title":"J Hepatol"},{"key":"hep41088-bib-0045-20240114","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0168-8278(92)90029-O","article-title":"Liver damage from flucloxacillin, cloxacillin and dicloxacillin","volume":"15","year":"1992","journal-title":"J Hepatol"},{"key":"hep41088-bib-0046-20240114","first-page":"1232","article-title":"Drug and toxin\u2010induced bile duct disorders","volume":"15","year":"2000","journal-title":"J Gastroenterol Hepatol"},{"key":"hep41088-bib-0048-20240114","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0168-8278(05)80476-3","article-title":"Antibiotic\u2010associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis","volume":"20","year":"1994","journal-title":"J Hepatol"},{"key":"hep41088-bib-0049-20240114","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/0016-5085(92)90780-3","article-title":"Carbamazepine hepatotoxicity: another cause of the vanishing bile duct syndrome","volume":"102","year":"1992","journal-title":"Gastroenterology"},{"key":"hep41088-bib-0050-20240114","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/00042737-200209000-00014","article-title":"Reversible vanishing bile duct syndrome induced by carbamazepine","volume":"14","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"hep41088-bib-0051-20240114","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1592\/phco.30.9.953","article-title":"Meropenem\u2010induced vanishing bile duct syndrome","volume":"30","year":"2010","journal-title":"Pharmacotherapy"},{"key":"hep41088-bib-0052-20240114","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1097\/01.pas.0000213342.78475.48","article-title":"Restoration of bile ducts in drug\u2010induced vanishing bile duct syndrome due to zonisamide","volume":"30","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"hep41088-bib-0053-20240114","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.crad.2005.01.006","article-title":"Bile duct complications of hepatic arterial infusion chemotherapy evaluated by helical CT","volume":"60","year":"2005","journal-title":"Clin Radiol"},{"key":"hep41088-bib-0054-20240114","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.crad.2006.02.013","article-title":"Chemotherapy\u2010induced sclerosing cholangitis","volume":"61","year":"2006","journal-title":"Clin Radiol"},{"key":"hep41088-bib-0055-20240114","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF00571690","article-title":"Methimazole\u2010induced cholestatic liver injury, mimicking sclerosing cholangitis","volume":"381","year":"1996","journal-title":"Langenbecks Arch Chir"},{"key":"hep41088-bib-0056-20240114","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/ajg.2010.485","article-title":"Ketamine\u2010induced cholangiopathy: a case report","volume":"106","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"hep41088-bib-0057-20240114","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/hep.26459","article-title":"Ketamine abuse, biliary tract disease, and secondary sclerosing cholangitis","volume":"58","year":"2013","journal-title":"Hepatology"},{"key":"hep41088-bib-0058-20240114","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1007\/s10620-015-3914-3","article-title":"Docetaxel induced sclerosing cholangitis","volume":"60","year":"2015","journal-title":"Dig Dis Sci"},{"key":"hep41088-bib-0059-20240114","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.dld.2015.03.002","article-title":"Secondary sclerosing cholangitis in patients with drug\u2010induced liver injury","volume":"47","year":"2015","journal-title":"Dig Liv Dis"},{"key":"hep41088-bib-0060-20240114","first-page":"65A","article-title":"Drug induced liver injury associated with sclerosing cholangitis like changes on magnetic resonance cholangiography imaging","volume":"64","year":"2016","journal-title":"[Abstract] Hepatology"},{"key":"hep41088-bib-0061-20240114","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1111\/j.1365-2036.2007.03330.x","article-title":"The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug\u2010induced liver injury","volume":"25","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"hep41088-bib-0062-20240114","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/hep.24527","article-title":"Drug\u2010Induced liver injury with hypersensitivity features has a better outcome: a single\u2010center experience of 39 children and adolescents","volume":"54","year":"2011","journal-title":"Hepatology"},{"key":"hep41088-bib-0063-20240114","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/jcp.2008.058248","article-title":"Histological patterns in drug\u2010induced liver disease","volume":"62","year":"2009","journal-title":"J Clin Pathol"},{"key":"hep41088-bib-0064-20240114","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1152\/physrev.00027.2002","article-title":"Bile salt transporters: molecular characterization, function, and regulation","volume":"83","year":"2003","journal-title":"Physiol Rev"},{"key":"hep41088-bib-0065-20240114","doi-asserted-by":"crossref","first-page":"251","DOI":"10.5858\/1999-123-0251-SICCBA","article-title":"Severe intrahepatic cholestasis caused by amiodarone toxicity after withdrawal of the drug: a case report and review of the literature","volume":"123","year":"1999","journal-title":"Arch Pathol Lab Med"},{"key":"hep41088-bib-0066-20240114","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2796.1992.tb00562.x","article-title":"Drug\u2010induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987","volume":"232","year":"1992","journal-title":"J Intern Med"},{"key":"hep41088-bib-0067-20240114","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/gut.33.3.368","article-title":"Hepatitis associated with amoxycillin\u2010clavulanic acid combination report of 15 cases","volume":"33","year":"1992","journal-title":"Gut"},{"key":"hep41088-bib-0068-20240114","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/hep.28323","article-title":"Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports","volume":"63","year":"2016","journal-title":"Hepatology"},{"key":"hep41088-bib-0069-20240114","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/00365520510023846","article-title":"Fulminant drug\u2010induced hepatic failure leading to death or liver transplantation in Sweden","volume":"40","year":"2005","journal-title":"Scand J Gastroenterol"},{"key":"hep41088-bib-0070-20240114","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1053\/j.gastro.2008.09.011","article-title":"Causes, clinical features, and outcomes from a prospective study of drug\u2010induced liver injury in the United States","volume":"135","year":"2008","journal-title":"Gastroenterology"},{"key":"hep41088-bib-0071-20240114","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/01.meg.0000250581.77865.68","article-title":"Antibiotic therapy: a major cause of drug\u2010induced jaundice in southwest England","volume":"19","year":"2007","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"hep41088-bib-0072-20240114","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/hep.21324","article-title":"Determinants of the clinical expression of amoxicillin\u2010clavulanate hepatotoxicity: a prospective series from Spain","volume":"44","year":"2006","journal-title":"Hepatology"},{"key":"hep41088-bib-0073-20240114","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/archinte.1996.00440110099013","article-title":"Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid","volume":"156","year":"1996","journal-title":"Arch Intern Med."},{"key":"hep41088-bib-0074-20240114","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1007\/s10620-016-4121-6","article-title":"Amoxicillin\u2010clavulanate\u2010induced liver injury","volume":"61","year":"2016","journal-title":"Dig Dis Sci"},{"key":"hep41088-bib-0075-20240114","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s10620-005-2938-5","article-title":"Acute liver failure due to amoxicillin and amoxicillin\/clavulanate","volume":"50","year":"2005","journal-title":"Dig Dis Sci"},{"key":"hep41088-bib-0076-20240114","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/bmj.306.6872.233","article-title":"Risk factors for development of flucloxacillin associated jaundice","volume":"306","year":"1993","journal-title":"BMJ"},{"key":"hep41088-bib-0077-20240114","doi-asserted-by":"crossref","first-page":"701","DOI":"10.5694\/j.1326-5377.1989.tb139652.x","article-title":"Prolonged hepatic cholestasis after flucloxacillin therapy","volume":"151","year":"1989","journal-title":"Med J Aust"},{"key":"hep41088-bib-0078-20240114","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cld.2007.06.009","article-title":"Hepatotoxicity due to antibiotics","volume":"11","year":"2007","journal-title":"Clin Liver Dis"},{"key":"hep41088-bib-0079-20240114","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/clinids\/20.4.1073","article-title":"Clarithromycin\u2010induced hepatotoxicity","volume":"20","year":"1995","journal-title":"Clin Infect Dis"},{"key":"hep41088-bib-0080-20240114","doi-asserted-by":"crossref","first-page":"810","DOI":"10.2146\/ajhp080687","article-title":"Azithromycin\u2010induced liver injury","volume":"67","year":"2010","journal-title":"Am J Health Syst Pharm."},{"key":"hep41088-bib-0081-20240114","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cgh.2014.07.054","article-title":"Clinical and histologic features of azithromycin\u2010induced liver injury","volume":"13","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep41088-bib-0082-20240114","first-page":"175","article-title":"Trimethoprim\u2010sulfamethoxazole\u2010associated hepatotoxicity \u2010 part of a hypersensitivity syndrome","volume":"10","year":"2003","journal-title":"Can J Clin Pharmacol"},{"key":"hep41088-bib-0083-20240114","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3109\/00365529709007690","article-title":"Liver reactions to oral low\u2010dose tetracyclines","volume":"32","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"hep41088-bib-0084-20240114","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1365-2710.2007.00853.x","article-title":"Association between tetracycline or doxycycline and hepatotoxicity: a population based case\u2010control study","volume":"32","year":"2007","journal-title":"J Clin Pharm Ther"},{"key":"hep41088-bib-0085-20240114","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJM199904223401617","article-title":"Terbinafine and fulminant hepatic failure","volume":"340","year":"1999","journal-title":"N Engl J Med"},{"key":"hep41088-bib-0086-20240114","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/0168-8278(95)80045-X","article-title":"Cholestatic hepatitis related to quinolones: a report of two cases","volume":"23","year":"1995","journal-title":"J Hepatol"},{"key":"hep41088-bib-0087-20240114","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.cgh.2011.02.019","article-title":"Clinical and histopathologic features of fluoroquinolone\u2010induced liver injury","volume":"9","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep41088-bib-0088-20240114","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S0168-8278(02)00268-4","article-title":"Delayed and prolonged cholestatic hepatitis with ductopenia after long\u2010term ciprofloxacin therapy for Crohn's disease","volume":"37","year":"2002","journal-title":"J Hepatol"},{"key":"hep41088-bib-0089-20240114","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1055\/s-0034-1375964","article-title":"Severe ductopenia and cholestasis from levofloxacin drug\u2010induced liver injury: a case report and review","volume":"34","year":"2014","journal-title":"Semin Liver Dis"},{"key":"hep41088-bib-0090-20240114","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.cgh.2014.11.036","article-title":"Identification and characterization of cefazolin\u2010induced liver injury","volume":"13","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep41088-bib-0091-20240114","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/j.1365-2036.2010.04449.x","article-title":"Duloxetine hepatotoxicity: a case\u2010series from the drug\u2010induced liver injury network","volume":"32","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"hep41088-bib-0092-20240114","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/MCG.0000000000000568","article-title":"Azathioprine and 6\u2010mercaptopurine\u2010induced liver injury: clinical features and outcomes","volume":"51","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"hep41088-bib-0093-20240114","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.dld.2009.03.004","article-title":"Severe cholestatic acute hepatitis following azathioprine therapy in a patient with ulcerative pancolitis","volume":"41","year":"2009","journal-title":"Dig Liver Dis"},{"key":"hep41088-bib-0094-20240114","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1155\/1998\/294752","article-title":"Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity","volume":"12","year":"1998","journal-title":"Can J Gastroenterol"},{"key":"hep41088-bib-0095-20240114","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1365-2036.2005.02636.x","article-title":"Incidence, risk factors and clinical course of thiopurine\u2010induced liver injury in patients with inflammatory bowel disease","volume":"22","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"hep41088-bib-0096-20240114","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1111\/j.1572-0241.2007.01187.x","article-title":"Thiopurine\u2010induced liver injury in patients with inflammatory bowel disease: a systematic review","volume":"102","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"hep41088-bib-0097-20240114","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1872-034X.2007.00115.x","article-title":"Clinical and pathological features of a prolonged type of acute intrahepatic cholestasis","volume":"37","year":"2007","journal-title":"Hepatol Res"},{"key":"hep41088-bib-0098-20240114","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0016-5085(98)70154-4","article-title":"Drug\u2010associated acute\u2010onset vanishing bile duct and Stevens\u2010Johnson syndromes in a child","volume":"115","year":"1998","journal-title":"Gastroenterology"},{"key":"hep41088-bib-0099-20240114","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3109\/13625189809167479","article-title":"Sex hormonal preparations and the liver","volume":"3","year":"1998","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"hep41088-bib-0100-20240114","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2796.1993.tb00745.x","article-title":"Liver damage from low\u2010dose oral contraceptives","volume":"234","year":"1993","journal-title":"J Intern Med"},{"key":"hep41088-bib-0102-20240114","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3748\/wjg.15.1677","article-title":"Bile\u2010acid\u2010induced cell injury and protection","volume":"15","year":"2009","journal-title":"World J Gastroenterol"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep4.1088","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep4.1088","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep4.1088","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/02009842-201710000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T17:01:10Z","timestamp":1705251670000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/02009842-201710000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,11]]},"references-count":100,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1002\/hep4.1088","relation":{},"ISSN":["2471-254X","2471-254X"],"issn-type":[{"value":"2471-254X","type":"print"},{"value":"2471-254X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,11]]}}}